scholarly journals Transmission of COVID-19 Virus in the Presence of Neurologic Manifestations

Author(s):  
Morteza Karimian ◽  
Morteza Karimian ◽  
Hamidreza Famitafreshi

COVID-19 is a viral disease with a different set of manifestations. However, all clinical manifestations are not occurring at the same time and some patients present the disease with an isolated or even without any specific symptoms. This disease besides neurologic symptoms in rare cases even presents itself with other symptoms such as cardiac failure. In this case, a health care provider may not aware of this situation. In these situations, the transmission of the virus to individuals remains and people may not be aware of the high-risk situation. It is suggested to be aware of different clinical manifestations of COVID-19 disease and preventive strategies keep for all patients.

2012 ◽  
Author(s):  
Kelly R. Theim ◽  
Meghan M. Sinton ◽  
Richard I. Stein ◽  
Brian E. Saelens ◽  
Sucheta C. Thekkedam ◽  
...  

1983 ◽  
Vol 36 (4) ◽  
pp. 459-463 ◽  
Author(s):  
J.L. Larrea ◽  
L. Núñez ◽  
J.A. Reque ◽  
M. Gil Aguado ◽  
R. Matarros ◽  
...  

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 4076-4076 ◽  
Author(s):  
Mario von Depka ◽  
Don Shaffer ◽  
Francesco Baudo ◽  
Caroline Shiach ◽  
Johan Frieling ◽  
...  

Abstract Congenital antithrombin (AT) deficiency is a major cause of thrombophilia. Prophylactic AT replacement in high risk situations may be considered for these patients as AT deficiency may lead to insufficient anticoagulation resulting in acute deep venous thrombosis (DVT), which cannot be treated by higher doses of heparin. This multicenter, multinational treatment study is the first to investigate rhAT, derived from transgenic goats, in patients with a personal or family history of DVT and previously documented AT activity < 60% of normal undergoing elective surgery, delivery or Cesarean section. IV rhAT was administered as continuous infusion to maintain AT activity between 80% and 120% of normal. Dose adjustments could be made based on AT assessments. Treatment was initiated prior to the high risk situation and continued for the duration of the high-risk period, with a minimum of 3 days. Standardized duplex ultrasound scans (US) were done prior to treatment, at fixed time points after initiation of treatment and when clinically indicated. Scans were assessed for the presence of DVT locally and videotaped for blinded central evaluation. Primary efficacy assessment was the incidence of acute DVT in the first 30 days after the high risk situation. Fourteen patients (4 hip replacements, 1 bilateral breast reduction, and 9 deliveries) were included. Loading and maintenance rhAT dosing increased and sustained AT activity levels within or close to the normal AT activity range. At central evaluation, one patient suffered from acute DVT at baseline, prior to administration of rhAT and was excluded from the evaluation of efficacy. None of the patients showed clinical symptoms of DVT or other thromboembolic events at any time during rhAT administration or up to 30 days after last day of dosing. One patient, who was clinically asymptomatic, was diagnosed by local and central evaluation with acute DVT by scheduled US evaluation at the intended last day of dosing. Although the patient was asymptomatic, treatment with rhAT was continued. The patient remained asymptomatic and the DVT resolved at follow-up US. At 7 days follow-up one patient was diagnosed as having an acute DVT by central evaluation but not by local evaluation. The patient was asymptomatic during the whole treatment and follow-up, and no action was taken. Thus, the frequency of acute DVT assessed by blinded central and local review was 1/13 (7%). Treatment with rhAT was well tolerated. None of the reported adverse events in patients or newborns was assessed as related to rhAT treatment. There were no signs of allergic or anaphylactic reactions to rhAT and no evidence of antibodies to rhAT up to 90 days follow-up. This is the first study to evaluate AT replacement in hereditary AT deficient patients with screening US determinations. However, the lack of clinically apparent DVT in this study is similar to other comparable AT replacement studies. We therefore conclude that prophylactic administration of rhAT to hereditary AT deficient patients in high-risk situations is safe and effective for the prevention of thromboembolic events.


2020 ◽  
Vol 9 (6) ◽  
pp. 1753 ◽  
Author(s):  
Jacek Baj ◽  
Hanna Karakuła-Juchnowicz ◽  
Grzegorz Teresiński ◽  
Grzegorz Buszewicz ◽  
Marzanna Ciesielka ◽  
...  

Coronavirus disease 2019 (COVID-19), due to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has become an epidemiological threat and a worldwide concern. SARS-CoV-2 has spread to 210 countries worldwide and more than 6,500,000 confirmed cases and 384,643 deaths have been reported, while the number of both confirmed and fatal cases is continually increasing. COVID-19 is a viral disease that can affect every age group—from infants to the elderly—resulting in a wide spectrum of various clinical manifestations. COVID-19 might present different degrees of severity—from mild or even asymptomatic carriers, even to fatal cases. The most common complications include pneumonia and acute respiratory distress syndrome. Fever, dry cough, muscle weakness, and chest pain are the most prevalent and typical symptoms of COVID-19. However, patients might also present atypical symptoms that can occur alone, which might indicate the possible SARS-CoV-2 infection. The aim of this paper is to review and summarize all of the findings regarding clinical manifestations of COVID-19 patients, which include respiratory, neurological, olfactory and gustatory, gastrointestinal, ophthalmic, dermatological, cardiac, and rheumatologic manifestations, as well as specific symptoms in pediatric patients.


2018 ◽  
Vol 3 (3) ◽  
pp. 2473011418S0048
Author(s):  
Kar Teoh ◽  
Kartik Hariharan

Category: Other Introduction/Purpose: Traditionally, a dorsal cheilectomy of the first metatarsophalangeal (MTP) joint is performed with an open approach through a dorsomedial or midmedial incision. It is now possible to perform minimally invasive dorsal cheilectomy (MIDC) of the first metatarsal with a wedge burr. The stab incision for MIDC needs to be dorsomedial to allow an ergonomic sweeping movement of the burr. This potentially puts the dorsomedial cutaneous nerve (DMCN) to the hallux at risk. There have been no clinical or cadaveric studies to date quantifying the risk to the DMCN and the surrounding structures when a Wedge burr was used for MIDC. We aim to determine this by using fresh-frozen cadaveric specimens in a “high-risk” situation in which most of the surgeons were novices to the technique. Methods: A total of 13 fresh-frozen cadaveric specimens (7 right, 6 left) amputated below the knee were obtained for this study. 13 foot and ankle surgeons (2 left handed, 11 right handed) who had no or minimal experience in MI surgery participated in this study. After a demonstration by an experienced MI surgeon and a practice on sawbones by participants, each surgeon performed a MIDC over the first metatarsal. Fluoroscopic guidance was available throughout the procedure. After the procedure, the specimens were dissected and the DMCN and the extensor hallucis longus (EHL) were inspected for damage. The same dissection steps were used for each specimen. The relationship of the DMCN to landmarks were measured. All measurements were made to the nearest millimetre. Results: Dissection of the specimens revealed that the DMCN to the hallux was cut completely in two specimens (15%). All the EHL tendon were intact, although in one specimen, the tendon showed some fraying on the underside of the tendon, estimated to be 15%. The average distance of the stab incision from the first MTP joint was 17.7 (range: 10 – 23) mm. In terms of the relationship of the DMCN to the stab incision in specimens where the DMCN was not cut, the DMCN was superior in five specimens and inferior in six specimens. The distance of the DMCN to the incision was 3.8 (range: 0 -7) mm. Conclusion: The DMCN to the hallux has been well studied by several authors and has a variable course. This nerve is at high risk of being damaged with open surgery and is a commonly reported complication of surgery to the hallux with rates reportedly as high as 45%. This nerve was damaged in 15% of our specimens following MIDC in a “high-risk” situation. Patients need to be specifically made aware of this risk when being consented for surgery. A carefully made working capsular pocket for the burr and marking this nerve before placing the incision if palpable could mitigate this risk.


2015 ◽  
Vol 47 ◽  
pp. 810
Author(s):  
Ivana Baralic ◽  
Nenad Dikic ◽  
Marija Andjelkovic ◽  
Zeljko Mojsilovic ◽  
Tanja Jeremic Velimirovc ◽  
...  

2021 ◽  
Author(s):  
Alexander Lampel ◽  
Daniela Schultz-Lampel

ZusammenfassungDas Blasenkarzinom ist bei Frauen ein eher seltener Tumor. In der noch selteneren Konstellation eines invasiven Karzinoms oder in einer High-Risk-Situation mit der Indikation der Zystektomie stellt sich die Frage nach der adäquaten Harnableitung.Die Wahl der Harnableitung wird bestimmt von den vorliegenden individuellen Gegebenheiten seitens des Tumors, der Patientin und den Erfahrungen und Präferenzen des Operateurs.Für den Blasenersatz steht eine ganze Palette an Alternativen zur Verfügung. Die Entscheidung muss zunächst zwischen den Optionen einer inkontinenten Ableitung mit Stomaanlage wie Ureterokutaneostomie oder Ileum-Conduit und den wesentlich aufwendigeren Techniken der kontinenten Varianten des orthotopen oder heterotopen Ersatzes getroffen werden.Dabei sind bei Frauen die vorliegenden Erfahrungen mit den kontinenten Varianten deutlich geringer als bei Männern und vor allem der orthotope Anschluß an die Harnröhre beinhaltet im Gegensatz zu den inkontinenten Formen des Blasenersatzes und der heterotopen Ableitung geschlechtsspezifische Unterschiede.Für die verschiedenen Varianten gibt es insgesamt klare Ein- oder Ausschlußkriterien. Schwierig wird es eher in Graubereichen, für welche Form der Harnableitung man sich vor dem Eingriff entscheidet. Auf keinen Fall kann dies generell, sondern muss in jedem Fall individuell entschieden werden. Dafür bedarf es unter anderem auch umfangreicher Kenntnisse seitens des Operateurs über die verschiedenen Optionen der Operationsmethoden, deren Probleme und Komplikationsmöglichkeiten sowie insbesondere auch deren Beherrschung.


Sign in / Sign up

Export Citation Format

Share Document